全文获取类型
收费全文 | 5244篇 |
免费 | 527篇 |
国内免费 | 276篇 |
专业分类
电工技术 | 36篇 |
综合类 | 179篇 |
化学工业 | 1554篇 |
金属工艺 | 164篇 |
机械仪表 | 132篇 |
建筑科学 | 648篇 |
矿业工程 | 37篇 |
能源动力 | 17篇 |
轻工业 | 1305篇 |
水利工程 | 56篇 |
石油天然气 | 18篇 |
无线电 | 206篇 |
一般工业技术 | 666篇 |
冶金工业 | 416篇 |
原子能技术 | 81篇 |
自动化技术 | 532篇 |
出版年
2024年 | 9篇 |
2023年 | 176篇 |
2022年 | 212篇 |
2021年 | 928篇 |
2020年 | 299篇 |
2019年 | 271篇 |
2018年 | 178篇 |
2017年 | 211篇 |
2016年 | 204篇 |
2015年 | 225篇 |
2014年 | 352篇 |
2013年 | 318篇 |
2012年 | 271篇 |
2011年 | 302篇 |
2010年 | 287篇 |
2009年 | 277篇 |
2008年 | 260篇 |
2007年 | 253篇 |
2006年 | 181篇 |
2005年 | 146篇 |
2004年 | 133篇 |
2003年 | 111篇 |
2002年 | 104篇 |
2001年 | 48篇 |
2000年 | 56篇 |
1999年 | 26篇 |
1998年 | 38篇 |
1997年 | 26篇 |
1996年 | 18篇 |
1995年 | 21篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1977年 | 2篇 |
1968年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
1960年 | 2篇 |
1959年 | 1篇 |
1958年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有6047条查询结果,搜索用时 15 毫秒
41.
Effects of yoghurt butter oils on rat plasma lipids,haematology and liver histology parameters in a 150‐day study 下载免费PDF全文
Mohammadmehdi Hassanzadeh‐Taheri Mahsa Hassanzadeh‐Taheri Farnaz Jahani Mehran Hosseini 《International Journal of Dairy Technology》2018,71(1):140-148
Although yoghurt butter oil as a fermented dairy product is widely consumed in several countries, its metabolic effects have not been fully elucidated. In this study, male Wistar rats were treated with standard diet, standard diet enriched with 10% or 20% (W/W) of either cow yoghurt butter oil (CYBO), sheep yoghurt butter oil (SYBO) or cottonseed oil (COT) for 20 weeks. Treatment of rats with CYBO or SYBO (at both concentrations) did not significantly influence haematological parameters, plasma lipids and liver histological structure. However, in contrast to popular belief, COT treatment at the higher dose induced leukocytosis, dyslipidaemia and liver steatosis. 相似文献
42.
Dr. Pui-Ying Lam Dr. Peter Kutchukian Rajan Anand Dr. Jason Imbriglio Dr. Christine Andrews Hugo Padilla Anita Vohra Sarah Lane Dann L. Parker Jr. Dr. Ivan Cornella Taracido Dr. Douglas G. Johns Dr. Manu Beerens Dr. Calum A. MacRae John P. Caldwell Dr. Steve Sorota Dr. Aarti Asnani Dr. Randall T. Peterson 《Chembiochem : a European journal of chemical biology》2020,21(13):1905-1910
Doxorubicin is a highly effective chemotherapy agent used to treat many common malignancies. However, its use is limited by cardiotoxicity, and cumulative doses exponentially increase the risk of heart failure. To identify novel heart failure treatment targets, a zebrafish model of doxorubicin-induced cardiomyopathy was previously established for small-molecule screening. Using this model, several small molecules that prevent doxorubicin-induced cardiotoxicity both in zebrafish and in mouse models have previously been identified. In this study, exploration of doxorubicin cardiotoxicity is expanded by screening 2271 small molecules from a proprietary, target-annotated tool compound collection. It is found that 120 small molecules can prevent doxorubicin-induced cardiotoxicity, including 7 highly effective compounds. Of these, all seven exhibited inhibitory activity towards cytochrome P450 family 1 (CYP1). These results are consistent with previous findings, in which visnagin, a CYP1 inhibitor, also prevents doxorubicin-induced cardiotoxicity. Importantly, genetic mutation of cyp1a protected zebrafish against doxorubicin-induced cardiotoxicity phenotypes. Together, these results provide strong evidence that CYP1 is an important contributor to doxorubicin-induced cardiotoxicity and highlight the CYP1 pathway as a candidate therapeutic target for clinical cardioprotection. 相似文献
43.
对高速路建设中高边坡病害的成因展开分析,并对高边坡病害的治理提出对策,希望对高边坡病害治理有一定的促进作用。 相似文献
44.
Madhu Ramesh Dr. Pushparathinam Gopinath Prof. Thimmaiah Govindaraju 《Chembiochem : a European journal of chemical biology》2020,21(8):1052-1079
The global burden of Alzheimer's disease (AD) is growing. Valiant efforts to develop clinical candidates for treatment have continuously met with failure. Currently available palliative treatments are temporary and there is a constant need to search for reliable disease pathways, biomarkers and drug targets for developing diagnostic and therapeutic tools to address the unmet medical needs of AD. Challenges in drug-discovery efforts raise further questions about the strategies of current conventional diagnosis; drug design; and understanding of disease pathways, biomarkers and targets. In this context, post-translational modifications (PTMs) regulate protein trafficking, function and degradation, and their in-depth study plays a significant role in the identification of novel biomarkers and drug targets. Aberrant PTMs of disease-relevant proteins could trigger pathological pathways, leading to disease progression. Advancements in proteomics enable the generation of patterns or signatures of such modifications, and thus, provide a versatile platform to develop biomarkers based on PTMs. In addition, understanding and targeting the aberrant PTMs of various proteins provide viable avenues for addressing AD drug-discovery challenges. This review highlights numerous PTMs of proteins relevant to AD and provides an overview of their adverse effects on the protein structure, function and aggregation propensity that contribute to the disease pathology. A critical discussion offers suggestions of methods to develop PTM signatures and interfere with aberrant PTMs to develop viable diagnostic and therapeutic interventions in AD. 相似文献
45.
46.
47.
吡非尼酮(pirfenidone, PFD)是新型的抗纤维化药物,在多个临床试验中证实能够延缓特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)患者肺功能下降速度,是治疗IPF的一线药物。与IPF发病机制相似的结缔组织病相关间质性肺疾病(connective tissue disease-associated interstitial lung diseases, CTD-ILD)的临床发生率较高,临床症状表现不明显,肺间质病变可能是唯一或最初的表现,临床表现异质性大,误诊率较高,同时也是导致患者死亡的重要原因之一,目前尚缺乏统一有效的指南或共识。有研究表明抗纤维化新药吡非尼酮在CTD-ILD的治疗中表现出一定潜力,本文对吡非尼酮治疗CTD-ILD的相关研究进展进行综述。 相似文献
48.
Diabetes mellitus is a major cause of chronic kidney disease and end-stage renal disease. However, the management of chronic kidney disease, particularly diabetes, requires vast improvements. Recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for the treatment of diabetes, have been shown to protect against kidney injury via glycemic control, as well as various other mechanisms, including blood pressure and hemodynamic regulation, protection from lipotoxicity, and uric acid control. As such, regulation of these mechanisms is recommended as an effective multidisciplinary approach for the treatment of diabetic patients with kidney disease. Thus, SGLT2 inhibitors are expected to become key drugs for treating diabetic kidney disease. This review summarizes the recent clinical evidence pertaining to SGLT2 inhibitors as well as the mechanisms underlying their renoprotective effects. Hence, the information contained herein will advance the current understanding regarding the pleiotropic effects of SGLT2 inhibitors, while promoting future research in the field. 相似文献
49.
Parul Singh Arun Rawat Bara Al-Jarrah Saras Saraswathi Hoda Gad Mamoun Elawad Khalid Hussain Mohammed A. Hendaus Wesam Al-Masri Rayaz A. Malik Souhaila Al Khodor Anthony K. Akobeng 《International journal of molecular sciences》2021,22(4)
Coeliac disease (CD) and Type 1 diabetes mellitus (T1DM) are immune-mediated diseases. Emerging evidence suggests that dysbiosis in the gut microbiome plays a role in the pathogenesis of both diseases and may also be associated with the development of neuropathy. The primary goal in this cross-sectional pilot study was to identify whether there are distinct gut microbiota alterations in children with CD (n = 19), T1DM (n = 18) and both CD and T1DM (n = 9) compared to healthy controls (n = 12). Our second goal was to explore the relationship between neuropathy (corneal nerve fiber damage) and the gut microbiome composition. Microbiota composition was determined by 16S rRNA gene sequencing. Corneal confocal microscopy was used to determine nerve fiber damage. There was a significant difference in the overall microbial diversity between the four groups with healthy controls having a greater microbial diversity as compared to the patients. The abundance of pathogenic proteobacteria Shigella and E. coli were significantly higher in CD patients. Differential abundance analysis showed that several bacterial amplicon sequence variants (ASVs) distinguished CD from T1DM. The tissue transglutaminase antibody correlated significantly with a decrease in gut microbial diversity. Furthermore, the Bacteroidetes phylum, specifically the genus Parabacteroides was significantly correlated with corneal nerve fiber loss in the subjects with neuropathic damage belonging to the diseased groups. We conclude that disease-specific gut microbial features traceable down to the ASV level distinguish children with CD from T1DM and specific gut microbial signatures may be associated with small fiber neuropathy. Further research on the mechanisms linking altered microbial diversity with neuropathy are warranted. 相似文献
50.
Khai Gene Leong Elyce Ozols John Kanellis Shawn S. Badal John T. Liles David J. Nikolic-Paterson Frank Y. Ma 《International journal of molecular sciences》2021,22(1)
Cyclophilins have important homeostatic roles, but following tissue injury, cyclophilin A (CypA) can promote leukocyte recruitment and inflammation, while CypD can facilitate mitochondrial-dependent cell death. This study investigated the therapeutic potential of a selective cyclophilin inhibitor (GS-642362), which does not block calcineurin function, in mouse models of tubular cell necrosis and renal fibrosis. Mice underwent bilateral renal ischemia/reperfusion injury (IRI) and were killed 24 h later: treatment with 10 or 30 mg/kg/BID GS-642362 (or vehicle) began 1 h before surgery. In the second model, mice underwent unilateral ureteric obstruction (UUO) surgery and were killed 7 days later; treatment with 10 or 30 mg/kg/BID GS-642362 (or vehicle) began 1 h before surgery. GS-642362 treatment gave a profound and dose-dependent protection from acute renal failure in the IRI model. This protection was associated with reduced tubular cell death, including a dramatic reduction in neutrophil infiltration. In the UUO model, GS-642362 treatment significantly reduced tubular cell death, macrophage infiltration, and renal fibrosis. This protective effect was independent of the upregulation of IL-2 and activation of the stress-activated protein kinases (p38 and JNK). In conclusion, GS-642362 was effective in suppressing both acute kidney injury and renal fibrosis. These findings support further investigation of cyclophilin blockade in other types of acute and chronic kidney disease. 相似文献